Related Experiment Video
Updated: Sep 17, 2025
A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
Published on: April 18, 2025
Cancer biomarkers discovered using pan-cancer plasma proteomic profiling.
Lin Bai1, Jiacheng Lyu1, Jinwen Feng1
1Clinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Department of Urology, Fudan University Shanghai Cancer Center, Center for Cell and Gene Therapy, Fudan University, Shanghai, China.
This study analyzed plasma proteomic profiles from over 2,000 cancer patients to identify novel diagnostic biomarkers for early cancer detection and monitoring treatment effectiveness.
Area of Science:
- Proteomics
- Biomarker Discovery
- Cancer Diagnostics
Background:
- Plasma proteomic data offers potential for improved cancer detection.
- Understanding proteomic profiles in cancer patients is crucial for developing diagnostic tools.
Purpose of the Study:
- To generate comprehensive plasma proteomic profiles from a large pan-cancer cohort.
- To identify and validate plasma biomarkers for cancer detection, subtyping, and treatment monitoring.
Main Methods:
- Mass spectrometry-based proteomics was employed to analyze plasma samples from 2,251 pan-cancer patients.
- Proteomic subtyping and classification models were developed and validated on an independent cohort.
Main Results:
- Proteomic features correlated with tumor types and clinical indicators, including tumor stage.
- A highly immune-activated subtype (renal and bladder cancers) exhibited distinct metabolic profiles.
- Plasma proteome patterns could differentiate between pre- and post-surgery states, indicating potential for monitoring therapeutic effects.
- Developed models accurately distinguished tumor types from healthy controls and enabled pan-cancer classification of potential biomarkers.
Conclusions:
- The study established a pan-cancer plasma proteomic landscape, highlighting potential diagnostic biomarkers.
- Plasma proteomic data, combined with clinical indicators, can aid in cancer detection, subtyping, and monitoring treatment response.
